Antibody therapeutics for epithelial ovarian cancer-Reference-Cited by-同舟云学术

Antibody therapeutics for epithelial ovarian cancer

Published:2022-11-02 Issue:11 Volume:22 Page:1379-1391
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Ruiz Mason¹,Zhang Ningyan¹,Sood Anil K²^ORCID,An Zhiqiang¹^ORCID

Affiliation:

1. Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas USA

2. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.2141565

Reference145 articles.

1. Ovarian Cancer Statistics. How common is ovarian cancer. Internet] [cited 2022 Jul 14]. Available from 2022 Jul 14: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html.

2. Ovarian Cancer Survival Rates. Ovarian cancer prognosis. Internet] [cited 2022 Jul 14]. Available from 2022 Jul 14: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html.

3. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial

4. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology;Frontiers in Immunology;2024-05-28

2. The application and outlook of proteomics in Ovarian Cancer, Breast Cancer, and Colon Cancer;BIO Web of Conferences;2024

3. A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022 (A Review);Russian Journal of Bioorganic Chemistry;2023-11